Webcast Alert: Lippert/Heilshorn Life Sciences Virtual Conference (Amarin Corporation Plc)
Posted on: Monday, 17 March 2008, 12:00 CDT
Amarin Corporation plc (AMRN) announces the following Webcast:
What: Lippert/Heilshorn Life Sciences Virtual Conference
When: March 18, 2008 @ 10:30 AM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=127009
How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Ben Carmichael, 212-838-3777, bcarmichael@lhai.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=127009 or http://www.investorcalendar.com/
Amarin Corporation plc, a neuroscience company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system (CNS) disorders in North America. It has a late-stage drug development pipeline, which includes Miraxion, a lead development compound in Phase III development for Huntington's disease; Phase II development for depressive disorders; and entering Phase IIa development for Parkinson's disease. The company's development pipeline also includes AMR-101, an oral formulation of Apomorphine for treating patients with advanced Parkinson's disease. Its other products in development include MCT-125, in Phase II development for the treatment of fatigue in patients suffering from multiple sclerosis; and LAX-201, under Phase II development, for depression in women. In addition, the company is evaluating new candidates for CNS disorders using combinatorial lipid chemistry technology and has two compounds in pre-clinical development for Parkinson's disease. Amarin Corporation has collaborations for its development programs with institutes, such as Trinity College; Max Planck Institute; University of Bradford; and University of Prince Edward Island. The company, formerly known as Ethical Holdings plc, was founded in 1989. Amarin Corporation is headquartered in London, the United Kingdom.
Source: Business Wire
Related Articles
- The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments
- Link Medicine Completes $40 Million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders
- Positron Corporation and Disease Management, LLC Sign Agreement to Co-Develop a Coronary Artery Disease Reversal and Prevention Software Program and Total Disease Management Solution
- PHC Initiates Phase I Alzheimer's Disease Trial
- PHC's Pivotal Research Initiates Largest Phase I Alzheimer's Disease Trial to Date for Major National Sponsor
- Highly Promising Dutch Research Into Alzheimer's Disease and Parkinson's Disease
- Ceregene Ends Phase II Enrollment for Parkinson's Disease
- Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
- Predix Pharmaceuticals Initiates Phase Ib Clinical Trials of 5-HT4 Agonist for Alzheimer's Disease and Other Cognitive Disorders
- Narrative Review: Celiac Disease: Understanding a Complex Autoimmune Disorder
 |
 |
User Comments (0)
RSS Feeds